Clinical Underestimation of Wearing-Off in Parkinson’s Disease: Patient-Reported Outcomes Versus Clinical Assessment and Impact on Quality of Life
Objective: To prospectively investigate the frequency and determinants of wearing-off (WO) in Parkinson's disease (PD) using a validated patient-reported instrument compared to routine neurological evaluation,…From Vision to Reality: Nursing Driven Implementation, Policy, and Safety Framework for Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in a Tertiary Movement Disorder Centre
Objective: To describe the development of nursing roles, policies, and safety processes supporting implementation of foslevodopa/foscarbidopa infusion therapy for advanced Parkinson’s disease in a tertiary…Improved “Good On” Time and Reduced Motor Fluctuations After Switching to IPX203: Interim Real-World Results from the First 111 Patients in ELEVATE PD
Objective: Evaluate interim outcomes from the real-world study of IPX203, assessing its impact to extend “Good On” time and reduce “Off” time in PD patients…Demographic And Clinical Characteristics Of Advanced Parkinson’s Disease Patients Receiving Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In The ELEGANCE Study: An Updated Interim Analysis
Objective: To describe the latest demographic and clinical profiles of patients with advanced Parkinson’s disease (aPD) enrolled in the ELEGANCE study who have received treatment…Inpatient Titration Protocol and Practical Implementation of Continuous Subcutaneous Foslevodopa/Foscarbidopa: Lessons from 28 Consecutive Cases
Objective: To describe inpatient titration methodology, dosing parameters, support services utilization, and early challenges in consecutive advanced PD patients. Background: Successful implementation of continuous subcutaneous…Clinical–Radiological Correlation in Patients with brain calcifications: a case series
Objective: The aim of this study was to describe a series of patients with brain calcifications within the Fahr spectrum and to analyze their clinical–radiological…Pharmacoscintigraphic Evaluation and Safety of a Novel, Dual-pulse, Delayed-release carbidopa/levodopa Tablet for Bedtime Dosing
Objective: To characterize the pharmacokinetics (PK) of carbidopa (CD) and levodopa (LD) from delayed-release (DR) tablets intended for bedtime administration and to correlate systemic exposure…Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Provides Sustained Improvement In Quality Of Life In Advanced Parkinson’s For Up To Two Years
Objective: To describe changes in health-related quality of life (QoL), assessed using the 8-item Parkinson’s Disease Questionnaire (PDQ-8), in people with advanced Parkinson’s disease (aPD)…Beyond Motor Fluctuations: Non-Motor and Quality-Of-Life Outcomes with Subcutaneous Foslevodopa/Foscarbidopa Infusion in Real-World Practice
Objective: To evaluate motor and non-motor outcomes, including sleep disturbances, of continuous subcutaneous foslevodopa/foscarbidopa infusion in a heterogeneous real-world cohort of patients with advanced Parkinson’s…Dopaminergic Medication Changes Following LFP-Guided Deep Brain Stimulation Programming in Parkinson’s Disease: A Single-Centre Audit
Objective: To evaluate changes in levodopa equivalent daily dose (LEDD) following deep brain stimulation (DBS) with local field potential (LFP)-guided programming in patients with Parkinson’s disease.…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 70
- Next Page »